Should expectations about the rate of new antiretroviral drug development impact the timing of HIV treatment initiation and expectations about treatment benefits?

Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet (2008) 7.70

Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91

Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med (2005) 2.38

The case for earlier treatment of HIV infection. Clin Infect Dis (2004) 2.20

Hit HIV-1 hard, but only when necessary. Lancet (2000) 1.98

When should antiretroviral therapy for HIV be started? BMJ (2007) 1.95

Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. J Antimicrob Chemother (2006) 1.70

When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Intern Med (2003) 1.63

Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Ann Intern Med (2008) 1.55

Estimating the rate of accumulating drug resistance mutations in the HIV genome. Value Health (2007) 1.26

Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS (2012) 1.26

Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal? Clin Infect Dis (2012) 0.84